Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
106-120 of 4127 results
Catalyst Pharmaceuticals’ neuromuscular drug succeeds in seven-patient trial
By PBR Staff Writer
Catalyst Pharmaceuticals said its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a debilitating neuromuscular disease, met the main goals of a study.
Contract Research & Services > Clinical Trials > News
AstraZeneca's Lynparza shows significant survival benefit in ovarian cancer study
By PBR Staff Writer
A phase 3 clinical trial evaluating AstraZeneca's PARP inhibitor Lynparza (olaparib) as maintenance therapy in ovarian cancer demonstrated a pronounced extension in survival compared to placebo.
Contract Research & Services > Clinical Trials > News
Indivior plans to file NDA for schizophrenia drug in Q4 2017
Indivior has unveield positive top-line 12-Month phase 3 results confirming long-term safety profile of RBP-7000 in patients with schizophrenia.
Contract Research & Services > Clinical Trials > News
Synairgen eyes lung fibrosis trial after positive data from LOXL2 inhibitor program
By PBR Staff Writer
Synairgen is on track to begin the initial clinical trial of a new lung fibrosis treatment later this year after pre-clinical work showed more evidence of improved breathing.
Contract Research & Services > Clinical Trials > News
BerGenBio signs deal with Merck to test lung and breast cancer combo
BerGenBio has signed a collaborative agreement with Merck focused the clinical study of BGB324 with Keytruda (pembrolizumab) in patients with advanced non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Contract Research & Services > Clinical Trials > News
Mereo BioPharma committee recommends continuation of BGS-649 study
Mereo BioPharma said that an independent data monitoring committee has recommended to continue all three different dose arms of the Phase 2b BGS-649 study after a prospectively defined interim analysis of safety and efficacy.
Contract Research & Services > Clinical Trials > News
TG Therapeutics’ cancer drug meets primary end point in phase 3 trial
By PBR Staff Writer
TG Therapeutics’ cancer drug, TG-1101 (ublituximab), in combination with AbbVie’s Imbruvica (ibrutinib), has met its primary end point in a phase 3 study in chronic lymphocytic leukemia (CLL) patients.
Contract Research & Services > Clinical Trials > News
FDA asks Scynexis to hold initiation of new clinical studies using IV formulation of SCY-078
Scynexis has been asked by the US Food and Drug Administration (FDA) to put a hold on the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until it finishes a review of all available pre-clinical and clinical data of the IV formulation of SCY-078.
Contract Research & Services > Clinical Trials > News
Chi-Med’s colorectal cancer drug shows positive results in phase 3 trial
Hutchison China MediTech has unveiled top-line results from FRESCO, its Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic colorectal cancer (“CRC”) in China, who failed at least two prior chemotherapies, including fluoropyrimidine, oxaliplatin and irinotecan
Contract Research & Services > Clinical Trials > News
PTC Therapeutics' cystic fibrosis drug fails in phase 3 trial
PTC Therapeutics’ protein restoration therapy ataluren failed to meet the primary and secondary endpoints in a phase 3 trial, dubbed Ataluren Confirmatory Trial (ACT CF), in patients with nonsense mutation cystic fibrosis (nmCF).
Contract Research & Services > Clinical Trials > News
Roche's Perjeta meets primary endpoint in breast cancer study
By PBR Staff Writer
A phase III study has demonstrated that Roche’s Perjeta regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin and chemotherapy.
Contract Research & Services > Clinical Trials > News
Amgen’s Blinatumomab nearly doubles survival time in B-Cell ALL
By PBR Staff Writer
A phase 3 study assessing Amgen’s Blincyto (blinatumomab) significantly improved overall survival (OS) in patients with B-Cell precursor acute lymphoblastic leukemia compared To chemotherapy.
Contract Research & Services > Clinical Trials > News
Kite Pharma's cancer therapy study shows good results in first CAR-T trial
By PBR Staff Writer
Kite Pharma’s axicabtagene ciloleucel demonstrated an objective response rate (ORR) of 82% and a complete response (CR) rate of 54% for patients with aggressive non-Hodgkin lymphoma in the ZUMA-1 trial.
Contract Research & Services > Clinical Trials > News
La Jolla’s blood pressure drug meets primary endpoint in phase 3 trial
By PBR Staff Writer
La Jolla Pharmaceutical’s catecholamine resistant hypotension (CRH) drug, LJPC-501 (angiotensin II) has met its primary endpoint in a phase 3 study.
Contract Research & Services > Clinical Trials > News
Oxford BioMedica’s TroVax phase I/II trial yields encouraging results
Oxford BioMedica announced that a phase I/II clinical trial of MVA-5T4 immunotherapy (TroVax) and low dose cyclophosphamide (CPM) has yielded encouraging results in patients with advanced colorectal cancer (TaCTiCC).
Contract Research & Services > Clinical Trials > News
106-120 of 4127 results